A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis.

IF 5 3区 医学 Q2 IMMUNOLOGY
Fu-Yao Jiang, Yan-Zhu Zhang, Yuan-Hong Tai, Chien-Yu Chou, Yu-Ching Hsieh, Ya-Chi Chang, Hsiao-Chen Huang, Zhi-Qin Li, Yuan-Chin Hsieh, I-Ju Chen, Bo-Cheng Huang, Yu-Cheng Su, Wen-Wei Lin, Hsin-Chieh Lin, Jui-I Chao, Shyng-Shiou F Yuan, Yun-Ming Wang, Tian-Lu Cheng, Shey-Cherng Tzou
{"title":"A lesion-selective albumin-CTLA4Ig as a safe and effective treatment for collagen-induced arthritis.","authors":"Fu-Yao Jiang,&nbsp;Yan-Zhu Zhang,&nbsp;Yuan-Hong Tai,&nbsp;Chien-Yu Chou,&nbsp;Yu-Ching Hsieh,&nbsp;Ya-Chi Chang,&nbsp;Hsiao-Chen Huang,&nbsp;Zhi-Qin Li,&nbsp;Yuan-Chin Hsieh,&nbsp;I-Ju Chen,&nbsp;Bo-Cheng Huang,&nbsp;Yu-Cheng Su,&nbsp;Wen-Wei Lin,&nbsp;Hsin-Chieh Lin,&nbsp;Jui-I Chao,&nbsp;Shyng-Shiou F Yuan,&nbsp;Yun-Ming Wang,&nbsp;Tian-Lu Cheng,&nbsp;Shey-Cherng Tzou","doi":"10.1186/s41232-023-00264-8","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>CTLA4Ig is a dimeric fusion protein of the extracellular domain of cytotoxic T-lymphocyte protein 4 (CTLA4) and an Fc (Ig) fragment of human IgG<sub>1</sub> that is approved for treating rheumatoid arthritis. However, CTLA4Ig may induce adverse effects. Developing a lesion-selective variant of CTLA4Ig may improve safety while maintaining the efficacy of the treatment.</p><p><strong>Methods: </strong>We linked albumin to the N-terminus of CTLA4Ig (termed Alb-CTLA4Ig) via a substrate sequence of matrix metalloproteinase (MMP). The binding activities and the biological activities of Alb-CTLA4Ig before and after MMP digestion were analyzed by a cell-based ELISA and an in vitro Jurkat T cell activation assay. The efficacy and safety of Alb-CTLA4Ig in treating joint inflammation were tested in mouse collagen-induced arthritis.</p><p><strong>Results: </strong>Alb-CTLA4Ig is stable and inactive under physiological conditions but can be fully activated by MMPs. The binding activity of nondigested Alb-CTLA4Ig was at least 10,000-fold weaker than that of MMP-digested Alb-CTLA4Ig. Nondigested Alb-CTLA4Ig was unable to inhibit Jurkat T cell activation, whereas MMP-digested Alb-CTLA4Ig was as potent as conventional CTLA4Ig in inhibiting the T cells. Alb-CTLA4Ig was converted to CTLA4Ig in the inflamed joints to treat mouse collagen-induced arthritis, showing similar efficacy to that of conventional CTLA4Ig. In contrast to conventional CTLA4Ig, Alb-CTLA4Ig did not inhibit the antimicrobial responses in the spleens of the treated mice.</p><p><strong>Conclusions: </strong>Our study indicates that Alb-CTLA4Ig can be activated by MMPs to suppress tissue inflammation in situ. Thus, Alb-CTLA4Ig is a safe and effective treatment for collagen-induced arthritis in mice.</p>","PeriodicalId":13588,"journal":{"name":"Inflammation and Regeneration","volume":null,"pages":null},"PeriodicalIF":5.0000,"publicationDate":"2023-02-16","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9933273/pdf/","citationCount":"1","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Inflammation and Regeneration","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1186/s41232-023-00264-8","RegionNum":3,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q2","JCRName":"IMMUNOLOGY","Score":null,"Total":0}
引用次数: 1

Abstract

Background: CTLA4Ig is a dimeric fusion protein of the extracellular domain of cytotoxic T-lymphocyte protein 4 (CTLA4) and an Fc (Ig) fragment of human IgG1 that is approved for treating rheumatoid arthritis. However, CTLA4Ig may induce adverse effects. Developing a lesion-selective variant of CTLA4Ig may improve safety while maintaining the efficacy of the treatment.

Methods: We linked albumin to the N-terminus of CTLA4Ig (termed Alb-CTLA4Ig) via a substrate sequence of matrix metalloproteinase (MMP). The binding activities and the biological activities of Alb-CTLA4Ig before and after MMP digestion were analyzed by a cell-based ELISA and an in vitro Jurkat T cell activation assay. The efficacy and safety of Alb-CTLA4Ig in treating joint inflammation were tested in mouse collagen-induced arthritis.

Results: Alb-CTLA4Ig is stable and inactive under physiological conditions but can be fully activated by MMPs. The binding activity of nondigested Alb-CTLA4Ig was at least 10,000-fold weaker than that of MMP-digested Alb-CTLA4Ig. Nondigested Alb-CTLA4Ig was unable to inhibit Jurkat T cell activation, whereas MMP-digested Alb-CTLA4Ig was as potent as conventional CTLA4Ig in inhibiting the T cells. Alb-CTLA4Ig was converted to CTLA4Ig in the inflamed joints to treat mouse collagen-induced arthritis, showing similar efficacy to that of conventional CTLA4Ig. In contrast to conventional CTLA4Ig, Alb-CTLA4Ig did not inhibit the antimicrobial responses in the spleens of the treated mice.

Conclusions: Our study indicates that Alb-CTLA4Ig can be activated by MMPs to suppress tissue inflammation in situ. Thus, Alb-CTLA4Ig is a safe and effective treatment for collagen-induced arthritis in mice.

Abstract Image

Abstract Image

Abstract Image

病变选择性白蛋白ctla4ig作为一种安全有效的治疗胶原性关节炎的药物。
背景:CTLA4Ig是细胞毒性t淋巴细胞蛋白4 (CTLA4)细胞外结构域的二聚体融合蛋白和人IgG1的Fc (Ig)片段,已被批准用于治疗类风湿性关节炎。然而,CTLA4Ig可能会引起不良反应。开发CTLA4Ig的病变选择性变体可以提高安全性,同时保持治疗的有效性。方法:我们通过基质金属蛋白酶(MMP)底物序列将白蛋白连接到CTLA4Ig的n端(称为Alb-CTLA4Ig)。采用细胞酶联免疫吸附法(ELISA)和体外Jurkat T细胞活化法分析MMP消化前后Alb-CTLA4Ig的结合活性和生物活性。在小鼠胶原性关节炎实验中,研究了Alb-CTLA4Ig治疗关节炎症的疗效和安全性。结果:Alb-CTLA4Ig在生理条件下稳定且无活性,但可被MMPs充分激活。未消化的Alb-CTLA4Ig的结合活性比mmp消化的Alb-CTLA4Ig的结合活性弱至少1万倍。未消化的Alb-CTLA4Ig不能抑制Jurkat T细胞的激活,而mmp消化的Alb-CTLA4Ig在抑制T细胞方面与常规CTLA4Ig一样有效。在炎症关节中将Alb-CTLA4Ig转化为CTLA4Ig治疗小鼠胶原性关节炎,其疗效与常规CTLA4Ig相似。与常规CTLA4Ig相比,Alb-CTLA4Ig不抑制处理小鼠脾脏的抗菌反应。结论:我们的研究表明,Alb-CTLA4Ig可被MMPs激活,原位抑制组织炎症。因此,Alb-CTLA4Ig是一种安全有效的治疗小鼠胶原性关节炎的药物。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
CiteScore
11.10
自引率
1.20%
发文量
45
审稿时长
11 weeks
期刊介绍: Inflammation and Regeneration is the official journal of the Japanese Society of Inflammation and Regeneration (JSIR). This journal provides an open access forum which covers a wide range of scientific topics in the basic and clinical researches on inflammation and regenerative medicine. It also covers investigations of infectious diseases, including COVID-19 and other emerging infectious diseases, which involve the inflammatory responses. Inflammation and Regeneration publishes papers in the following categories: research article, note, rapid communication, case report, review and clinical drug evaluation.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信